AF
PCVX icon

Amalgamated Financial’s Vaxcyte PCVX Stock Holding History

Amalgamated Financial’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$129K Buy
+5,357
New +$117K ﹤0.01% 2059

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Amalgamated Financial's PCVX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Vaxcyte (PCVX) in Q1 2022: 5,357 shares worth $129K. The stake represents ﹤0.01% of the portfolio and ranks #2059 among its holdings.

88 funds tracked by Wall St. Rank hold PCVX as of Q1 2022.

  • Amalgamated Financial held 5,357 shares of Vaxcyte worth $129K as of Q1 2022.
  • Vaxcyte was a new Amalgamated Financial position in Q1 2022.
  • Vaxcyte made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2059 holding.
  • 88 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.